We are live on
!
Find out more
FVFIGP
Flagship Ventures Fund IV General Partner Portfolio holdings
AUM
$585M
This Fund
S&P 500
This Quarter
Est. Return
+18.55%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$507M
AUM Growth
–
Cap. Flow
+$475M
Cap. Flow
% of AUM
93.74%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
3
New
3
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Seres Therapeutics
MCRB
|
+$463M |
| 2 |
TTOO
T2 Biosystems, Inc
TTOO
|
+$7.98M |
| 3 |
CARM
Carisma Therapeutics
CARM
|
+$4.16M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.4% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Seres Therapeutics
MCRB
$49.5M
| $494M | 97.53% |
+704,179
| New | +$463M |
|
|
TTOO
2
DELISTED
T2 Biosystems, Inc
TTOO
| $8.12M | 1.6% |
+148
| New | +$7.98M |
|
|
CARM
3
DELISTED
Carisma Therapeutics
CARM
| $4.41M | 0.87% |
+73,321
| New | +$4.16M |
|
Similar funds
ZA
VFS
WA
TT
ICAS
CPM
THSP
JWCA
Flagship Ventures Fund IV General Partner's Q4 2015 Portfolio in Review
Q4 2015 is the first quarter with a 13F filing on record for Flagship Ventures Fund IV General Partner, which disclosed 3 positions worth $507M. Its ten largest holdings account for 100% of the portfolio.
Its largest position is Seres Therapeutics: 704,179 shares worth $494M.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets.
- Flagship Ventures Fund IV General Partner's largest Q4 2015 buy was Seres Therapeutics: 704,179 shares worth $494M.
- Flagship Ventures Fund IV General Partner's ten largest holdings make up 100% of its $507M portfolio in Q4 2015.
- Flagship Ventures Fund IV General Partner disclosed 3 positions in Q4 2015, its first 13F filing on record.
Based on Flagship Ventures Fund IV General Partner's 13F filing for Q4 2015, filed 12 Feb 2016.